WO2005097755A3 - Imidazolderivate als hemmer von tyrosinkinase - Google Patents

Imidazolderivate als hemmer von tyrosinkinase Download PDF

Info

Publication number
WO2005097755A3
WO2005097755A3 PCT/EP2005/002746 EP2005002746W WO2005097755A3 WO 2005097755 A3 WO2005097755 A3 WO 2005097755A3 EP 2005002746 W EP2005002746 W EP 2005002746W WO 2005097755 A3 WO2005097755 A3 WO 2005097755A3
Authority
WO
WIPO (PCT)
Prior art keywords
tyrosine kinase
kinase inhibitors
imidazol derivatives
imidazol
derivatives
Prior art date
Application number
PCT/EP2005/002746
Other languages
English (en)
French (fr)
Other versions
WO2005097755A2 (de
Inventor
Guenter Hoelzemann
Helene Crassier
Alfred Jonczyk
Wolfgang Staehle
Arne Sutter
Wilfried Rautenberg
Francesc Mitjans
Elisabet Rosell-Vives
Jaume Adan
Riera Marta Soler
Original Assignee
Merck Patent Gmbh
Guenter Hoelzemann
Helene Crassier
Alfred Jonczyk
Wolfgang Staehle
Arne Sutter
Wilfried Rautenberg
Francesc Mitjans
Elisabet Rosell-Vives
Jaume Adan
Riera Marta Soler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Guenter Hoelzemann, Helene Crassier, Alfred Jonczyk, Wolfgang Staehle, Arne Sutter, Wilfried Rautenberg, Francesc Mitjans, Elisabet Rosell-Vives, Jaume Adan, Riera Marta Soler filed Critical Merck Patent Gmbh
Priority to JP2007505422A priority Critical patent/JP2007530609A/ja
Priority to US10/593,295 priority patent/US20070225347A1/en
Priority to EP05716076A priority patent/EP1761503A2/de
Priority to CA002561585A priority patent/CA2561585A1/en
Priority to AU2005231907A priority patent/AU2005231907A1/en
Priority to BRPI0508881-0A priority patent/BRPI0508881A/pt
Publication of WO2005097755A2 publication Critical patent/WO2005097755A2/de
Publication of WO2005097755A3 publication Critical patent/WO2005097755A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Verbindungen der Formel (I) worin R1 , R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, X und X' die in Anspruch 1 angegebenen Bedeutungen haben, sind Inhibitoren der Tyrosinkinasen, insbesondere TIE-2, und der Raf-­Kinasen und können u.a. zur Behandlung von Tumoren eingesetzt werden.
PCT/EP2005/002746 2004-03-29 2005-03-15 Imidazolderivate als hemmer von tyrosinkinase WO2005097755A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2007505422A JP2007530609A (ja) 2004-03-29 2005-03-15 イミダゾール誘導体
US10/593,295 US20070225347A1 (en) 2004-03-29 2005-03-15 Imidazole Derivatives
EP05716076A EP1761503A2 (de) 2004-03-29 2005-03-15 Imidazolderivate als hemmer von tyrosinkinase
CA002561585A CA2561585A1 (en) 2004-03-29 2005-03-15 Imidazol derivatives
AU2005231907A AU2005231907A1 (en) 2004-03-29 2005-03-15 Imidazol derivatives as tyrosine kinase inhibitors
BRPI0508881-0A BRPI0508881A (pt) 2004-03-29 2005-03-15 derivados de imidazol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004015099A DE102004015099A1 (de) 2004-03-29 2004-03-29 Imidazolderivate
DE102004015099.0 2004-03-29

Publications (2)

Publication Number Publication Date
WO2005097755A2 WO2005097755A2 (de) 2005-10-20
WO2005097755A3 true WO2005097755A3 (de) 2006-03-09

Family

ID=34981611

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/002746 WO2005097755A2 (de) 2004-03-29 2005-03-15 Imidazolderivate als hemmer von tyrosinkinase

Country Status (13)

Country Link
US (1) US20070225347A1 (de)
EP (1) EP1761503A2 (de)
JP (1) JP2007530609A (de)
KR (1) KR20060132965A (de)
CN (1) CN1938282A (de)
AR (1) AR048327A1 (de)
AU (1) AU2005231907A1 (de)
BR (1) BRPI0508881A (de)
CA (1) CA2561585A1 (de)
DE (1) DE102004015099A1 (de)
RU (1) RU2006138150A (de)
WO (1) WO2005097755A2 (de)
ZA (1) ZA200608998B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1858877E (pt) * 2005-01-14 2014-06-05 Gilead Connecticut Inc Ureias substituídas 1,3 diarilo, moduladoras da atividade de quinase
US7777040B2 (en) 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
JP2009533362A (ja) * 2006-04-12 2009-09-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング キナーゼ媒介性疾患を治療するための複素環式置換ビスアリール尿素のｎ−オキシド
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
CN103910714A (zh) * 2013-01-09 2014-07-09 天津泰瑞倍药研科技有限公司 氟代环丁烷基咪唑类化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040673A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Novel urea- and thiourea-type compounds
WO2003072541A2 (en) * 2001-09-27 2003-09-04 Smithkline Beecham Corporation Chemical compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040673A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Novel urea- and thiourea-type compounds
WO2003072541A2 (en) * 2001-09-27 2003-09-04 Smithkline Beecham Corporation Chemical compounds

Also Published As

Publication number Publication date
EP1761503A2 (de) 2007-03-14
US20070225347A1 (en) 2007-09-27
WO2005097755A2 (de) 2005-10-20
JP2007530609A (ja) 2007-11-01
BRPI0508881A (pt) 2007-09-11
RU2006138150A (ru) 2008-05-10
DE102004015099A1 (de) 2005-10-20
ZA200608998B (en) 2008-07-30
AU2005231907A1 (en) 2005-10-20
AR048327A1 (es) 2006-04-19
CN1938282A (zh) 2007-03-28
KR20060132965A (ko) 2006-12-22
CA2561585A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
MY153727A (en) Pyridazinone derivatives
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
WO2008017361A3 (de) 2-(heterocyclylbenzyl)-pyridazinonderivate
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
MX2009012708A (es) Derivados de piridazinona.
MX2007003470A (es) Compuestos de carbonilo los cuales pueden utilizarse como inhibidores del factor de coagulacion xa.
MX2010003368A (es) Derivados de imidazol.
WO2006125555A3 (de) Chinazolinone
ES2195785A1 (es) Nuevos derivados de piridazin-3(2h)-ona.
MX2009013077A (es) Derivados dde benzoxazolona.
HK1080470A1 (en) Heterocyclic compounds
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
WO2006084017A3 (en) Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
UA94570C2 (en) Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
WO2007120333A3 (en) Tetracyclic kinase inhibitors
ATE532781T1 (de) 5-(acylamino)indazol-derivate als kinase- inhibitoren
SG166100A1 (en) Novel compounds
MX2008002104A (es) Derivados de 1-acildihidropirazol.
MX2009012709A (es) Derivados de arileter-piridazinona.
TW200740816A (en) P38 MAP kinase inhibitors and methods for using the same
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
IL185539A0 (en) Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, preparation method compositions containing same and use
IL200469A0 (en) Benzimidazole derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005716076

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2398/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12006501731

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/010968

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2561585

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020067020089

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200580010619.X

Country of ref document: CN

Ref document number: 2007505422

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005231907

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006/08998

Country of ref document: ZA

Ref document number: 200608998

Country of ref document: ZA

Ref document number: 2006138150

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2005231907

Country of ref document: AU

Date of ref document: 20050315

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005231907

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020067020089

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10593295

Country of ref document: US

Ref document number: 2007225347

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2005716076

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0508881

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 10593295

Country of ref document: US